Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julio C Chavez

Showing results (31-40 of 132) with videos related to

Pageof 14
Sort By:
American Journal of Hematology|May 15, 2026
Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and ManagementJorge J Castillo, Brady E Beltrán, Jorge A Florindez, et al.
Critical Reviews in Oncology/Hematology|April 22, 2017
The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is nowLuis Miguel Juárez-Salcedo, Jose Sandoval-Sus, Lubomir Sokol, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2018
Feasibility and Efficacy of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for HIV-Associated Lymphoma: A Single-Institution ExperienceErnesto Ayala, Julio C Chavez, Alexandra Gomez, et al.
Expert Review of Hematology|November 12, 2022
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomesNicholas B Figura, Austin J Sim, Michael D Jain, et al.
American Journal of Hematology|April 21, 2016
EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and managementJorge J Castillo, Brady E Beltran, Roberto N Miranda, et al.
American Journal of Hematology|July 10, 2018
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and managementJorge J Castillo, Brady E Beltran, Roberto N Miranda, et al.
Leukemia & Lymphoma|May 1, 2015
The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecifiedBrady E Beltran, Christian Aguilar, Pilar Quiñones, et al.
American Journal of Hematology|April 26, 2022
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and managementLuis Malpica, Mario L Marques-Piubelli, Brady E Beltran, et al.
American Journal of Hematology|July 3, 2024
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and managementLuis Malpica, Mario L Marques-Piubelli, Brady E Beltran, et al.
Hematological Oncology|June 23, 2017
Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphomaBrady E Beltran, Pilar Quiñones, Domingo Morales, et al.
Pageof 14

Showing results (31-40 of 132) with videos related to

Sort By:
Pageof 14
American Journal of Hematology|May 15, 2026
Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and ManagementJorge J Castillo, Brady E Beltrán, Jorge A Florindez, et al.
Critical Reviews in Oncology/Hematology|April 22, 2017
The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is nowLuis Miguel Juárez-Salcedo, Jose Sandoval-Sus, Lubomir Sokol, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2018
Feasibility and Efficacy of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for HIV-Associated Lymphoma: A Single-Institution ExperienceErnesto Ayala, Julio C Chavez, Alexandra Gomez, et al.
Expert Review of Hematology|November 12, 2022
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomesNicholas B Figura, Austin J Sim, Michael D Jain, et al.
American Journal of Hematology|April 21, 2016
EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and managementJorge J Castillo, Brady E Beltran, Roberto N Miranda, et al.
American Journal of Hematology|July 10, 2018
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and managementJorge J Castillo, Brady E Beltran, Roberto N Miranda, et al.
Leukemia & Lymphoma|May 1, 2015
The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecifiedBrady E Beltran, Christian Aguilar, Pilar Quiñones, et al.
American Journal of Hematology|April 26, 2022
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and managementLuis Malpica, Mario L Marques-Piubelli, Brady E Beltran, et al.
American Journal of Hematology|July 3, 2024
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and managementLuis Malpica, Mario L Marques-Piubelli, Brady E Beltran, et al.
Hematological Oncology|June 23, 2017
Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphomaBrady E Beltran, Pilar Quiñones, Domingo Morales, et al.
Pageof 14